Abstract
Background
The introduction of specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly improved progression-free survival in hormone receptor-positive metastatic breast cancer. CDK 4/6 inhibitors induce cell cycle arrest via liberating the tumor suppressor retinoblastoma protein from CDK4/6 inhibitory effect. Preliminary studies suggested an increase in the hematological toxicities which might affect the quality of life in such palliative setting.
Methods
We searched PubMed, ASCO, ESMO and San Antonio meeting databases for randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors with safety data provided on the incidence of hematological adverse effects.
Results
Our search identified 1012 citations that were screened for relevance. Thirty-six studies were found to be potentially eligible. After excluding the ineligible studies, six studies were deemed to be eligible for meta-analysis. The risk ratio (RR) was 11.31 [95% confidence interval (CI) 8.06–15.87; p < 0.0001] for all-grade leucopenia, 14.86 (95% CI 11.37–19.41; p < 0.0001) for all-grade neutropenia, 9.04 (95% CI 3.78–21.63; p < 0.0001) for all-grade thrombocytopenia and 3.57 (95% CI 2.65–4.81; p < 0.0001) for all-grade anemia. The RR for grade 3/4 leucopenia was 33.86 (95% CI 14.59–78.57; p < 0.0001), for grade 3/4 neutropenia was 44.00 (95% CI 24.72–78.33; p < 0.0001), for grade 3/4 thrombocytopenia was 5.70 (95% CI 2.03–16.01; p = 0.001) and for grade 3/4 anemia was 2.80 (95% CI 1.45–5.41; p = 0.002). There was no significant increase in the RR of febrile neutropenia with RR of 3.29 (95% CI 0.93–11.57; p = 0.06).
Conclusion
Our analysis provides evidence that the use of CDK 4/6 inhibitors is associated with an increased risk of all-grade and high-grade hematological adverse events, which seems to be a class-effect, but not of febrile neutropenia compared with hormonal therapy alone.
http://ift.tt/2zHkxn1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου